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Abstract 
Background and Aims. Simple clinical algorithms including the Fatty Liver Index (FLI) and 
Lipid Accumulation Product (LAP) have been developed as a surrogate marker for Non-
Alcoholic Fatty Liver Disease (NAFLD). These algorithms have been constructed using 
ultrasonography, a semi-quantitative method. This study aimed to validate FLI and LAP as 
measures of hepatic steatosis, as measured quantitatively by proton magnetic resonance 
spectroscopy (1H-MRS). 
Methods. Data were collected from 168 patients with NAFLD and 168 controls who had 
undergone clinical, biochemical and anthropometric assessment in the course of research studies. 
Values of FLI and LAP were determined, and assessed both as predictors of the presence of 
hepatic steatosis (liver fat >5.5 %) and of actual liver fat content, as measured by 1H MRS. The 
discriminative ability of FLI and LAP was estimated using the area under the Receiver Operator 
Characteristic curve (AUROC). Since FLI can also be interpreted as a predictive probability of 
hepatic steatosis, we assessed how well calibrated it was in our cohort. Linear regression with 
prediction intervals was used to assess the ability of FLI and LAP to predict liver fat content. 
Results. FLI and LAP discriminated between patients with and without hepatic steatosis with an 
AUROC of 0.79 (IQR= 0.74, 0.84) and 0.78 (IQR= 0.72, 0.83), although quantitative prediction 
of liver fat content was unsuccessful. Additionally, the algorithms accurately matched the 
observed percentages of patients with hepatic steatosis in our cohort.  
Conclusions. FLI and LAP may be used clinically, and for metabolic and epidemiological 
research, to identify patients with hepatic steatosis, but not as surrogates for liver fat content. 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a major public health 
concern, being highly prevalent in the general population, particularly in individuals with 
features of the metabolic syndrome1. NAFLD encompasses a disease spectrum, ranging from 
simple steatosis, through to an inflammatory state (non-alcoholic steatohepatitis, NASH) and 
culminating in fibrosis and liver cirrhosis2. In addition to the known association with liver-
related morbidity and mortality, NAFLD patients have an increased risk of type 2 diabetes 
mellitus and cardiovascular disease3, 4. 
 
Liver transaminases and abdominal ultrasonography are insensitive in detecting NAFLD, with  
liver function tests normal in up to 79% of patients and ultrasonography requiring a moderately 
high liver fat for NAFLD to be recognised5. Only histological examination or proton magnetic 
resonance spectroscopy (1H MRS) can quantitatively assess liver fat (more exactly, 
hepatocellular lipid content)3, 4.  
 
Non-invasive algorithms based on metabolic and anthropometric variables, such as the fatty liver 
index (FLI), lipid accumulation product (LAP), the hepatic steatosis index (HIS) and the Finnish 
Diabetes Risk Score (FINDRISC)6-11, have been used as a screening test for hepatic steatosis, 
and identify potential patients for further clinical investigation or for epidemiologic studies. They 
have been applied in various clinical populations to assess prevalence of NAFLD 12 and to 
provide prognostic information about incident risk of metabolic syndrome and type 2 diabetes, 
cardiovascular disease and risk of mortality in various sub-groups13-18.  
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The original studies to propose FLI and LAP were validated using ultrasonography 2, 7, 19, as well 
as the SteatoTest, an alternative biochemical surrogate marker of liver steatosis20. Liver biopsy is 
an invasive method. The only study to validate FLI using 1H-MRS, which is supposed to be the 
next best method as compared with liver biopsy, involved only 25 subjects, with the results 
suggesting a nonlinear relationship between FLI and hepatocellular lipid content21. 
 
This study aimed to evaluate the ability of FLI and the LAP to discriminate between patients 
with and without hepatic steatosis, based on simple clinical and biochemical variables; and to 
evaluate their ability to predict liver fat content based on our non-invasive measurement of liver 
fat by 1H-MRS. Here we combined data from several large cohorts of participants with detailed 
characterisation of clinical, metabolic and anthropometric parameters, in whom 1H MRS 
measurement of liver fat had been performed for several different research projects.   
 
Materials and Methods  
Study participants. We analysed data from participants recruited into human metabolic studies 
from four research centres (University of Liverpool, University of Surrey, Charite University 
Berlin and German Institute of Human Nutrition, Potsdam-Rehbruecke). We recruited healthy 
controls and individuals with components of the metabolic syndrome including being 
overweight/obese (body mass index (BMI) >25kg/m2), with a waist circumference >80 cm in 
females and >94 cm in males, and with at least one additional feature of the metabolic syndrome 
according to International Diabetes Federation criteria22. Clinical characteristics of the cohorts 
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have been presented previously in detail23, 24. All participants gave written informed consent and 
ethical approval was obtained from the respective local ethics committee.  
 
Exclusion criteria. We excluded participants with a history of type 1 or 2 diabetes mellitus, 
pregnancy, any significant history of endocrine, cardiovascular, renal or hepatic disease, and 
standard MR contraindications. Other causes of chronic liver disease were excluded by taking a 
careful alcohol and drug history and performing an auto-immune liver screen and hepatitis 
serology.  
 
Anthropometric assessments. Trained physicians performed all anthropometry measurements. 
Body mass index (BMI) was calculated in kg/m2; waist circumference, was measured midway 
between the lower rib margin and the iliac crest.  
 
Biochemical assessment. All participants underwent a biochemical assessment and fasting 
triglycerides (fTG), alanine transferase (ALT) and gamma-glutamyl transferase (GGT) were 
measured. Routine laboratory markers were measured from venous blood samples using standard 
methods in the research laboratories of respective centres (University Hospital Aintree, 
Liverpool, Royal Surrey County Hospital and in the German Institute of Human Nutrition). 
 
Proton magnetic resonance spectroscopy (1H-MRS). Lipid content in the liver was measured by 
localized 1H MRS, using an Intera 1.5T Achieva (Philips Medical Systems, Best, The 
Netherlands)  for the Surrey participants25, a  Magnetom 1.5T Symphony MR (Siemens 
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Healthcare, Erlangen, Germany) for the Liverpool participants26, and a Magnetom 1.5T Avanto 
(Siemens Healthcare, Erlangen, Germany) for the German participants. Single voxel 
spectroscopy was used: for the German studies, STEAM with VOI 30 x30x30 mm, 32 
acquisitions, TR = 4000 ms, TM = 15 ms, TE = 10 ms; for the UK studies, PRESS with VOI 
20x20x20 mm (3 voxels, results averaged), 64 acquisitions, TR = 1500 ms, TE 135 ms25. Spectra 
were quantified using the AMARES algorithm included in the jMRUI software package, 
incorporating standard prior knowledge. For the German studies signal integrals of water (H2O at 
4.8 ppm) and lipids (CH2 and CH3 at 1.25 ppm and 0.95 ppm) were quantified manually in fixed 
frequency intervals (water: 3.1 – 6.2 ppm, lipids: 0.5 – 1.8 ppm); for the UK studies these signal 
amplitudes were obtained directly from the AMARES fit. Liver fat is expressed as % of CH2 
lipid signal amplitude relative to water signal amplitude after correcting for T1 and T225. Liver fat 
content (%) was quantified but also coded ordinally as none (≤5.5%) or present (>5.5%). 
 
Calculations  
FLI was calculated using BMI (kg/m2), serum triglyceride (mg/dl) and GGT (u/L) concentrations 
and waist circumference (cm) according to Bedogni et al 7 to obtain a score between 0 to 100: 
 
 
where
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LAP was calculated using serum triglycerides (mmol/l) and waist circumference (cm) using sex-
specific calculations9: 
 
 
 
 
Statistical Analysis. Baseline demographic variables are reported as means and standard 
deviations or median and interquartile range depending on their distribution. Distributional 
assumptions were assessed using Q-Q plots. Categorical variables are reported as frequencies 
and percentages. Statistical comparisons of patients with and without hepatic steatosis were 
undertaken for all demographic variables; Chi-squared tests were used for categorical variables 
and unpaired t-tests or Mann-Whitney U tests for continuous variables, depending on whether 
relevant distributional assumptions were met. 
 
To assess the ability of a variable to discriminate between patients with and without hepatic 
steatosis, Receiver Operator Characteristic (ROC) curves were constructed for FLI, LAP, BMI, 
waist circumference and ALT. In addition, for FLI and LAP, we measured a number of other 
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diagnostic statistics: the sensitivity, specificity, positive likelihood ratio and negative likelihood 
ratio at various cut-points.  
 
Since FLI can also be interpreted as a predictive probability for hepatic steatosis, we assessed 
how well calibrated FLI was in our patient cohort using a calibration plot27. To do so we grouped 
patients into deciles based on measured FLI, and within each decile calculated the proportion of 
patients with hepatic steatosis. If a variable is well-calibrated, the observed percentages should 
be close to the ‘line of equality’ which represents perfect calibration: roughly 50% of patients 
should have hepatic steatosis at an FLI of around 50 etc. 
 
Linear regression with 95% prediction intervals (PI) was used to determine whether liver fat 
content could be predicted using FLI or LAP alone. PIs are to be interpreted as the range of 
values for liver fat we would assign to a new patient with a given FLI/LAP with 95% 
‘confidence’. Linear regression assumptions were assessed using plots of residuals versus fitted 
values and Q-Q plots of the residuals. It was necessary to logarithmically transform both liver fat 
and LAP for these purposes; the linear regression line and prediction intervals, while linear on 
the log scale, are non-linear, non-constant and asymmetric on the original scale. For simplicity 
we evaluated their predictive performance at the mean FLI/LAP. 
 
Results  
Characteristics of the participants  
Table 1 reports the clinical, biochemical and anthropometric characteristics of the participants 
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(178 males [53%] and 158 females). Participants were sub-divided into two groups, healthy 
controls or hepatic steatosis, according to their liver fat measured by proton-magnetic resonance 
spectroscopy (liver fat <5.5%, healthy controls; >5.5% NAFLD). Using this threshold, 50% of 
participants (n=168) had hepatic steatosis (116 males [66%]) and 50% (n=168) were healthy 
controls (61 males [34%]). The two groups were mean-matched for age.   
 
Participants with hepatic steatosis were more obese, with significantly greater weight, BMI and 
waist circumference, than the healthy controls. Those with hepatic steatosis demonstrated 
multiple components of the metabolic syndrome with significantly greater serum fasting glucose 
[4.8 mmol/l (IQR= 4.5, 5.1) vs. 5.0mmol/l (IQR=4.7, 5.4)], triglycerides [1.0 mmol/l (IQR= 0.8, 
1.3) vs. 1.6mmol/l (IQR=1.1, 2.3)] and lower HDL concentrations [1.4 mmol/l (IQR= 1.2, 1.7) 
vs. 1.2mmol/l (IQR=1.1, 1.4)] than the healthy control group (Table 1).  
 
The median liver fat significantly differed in the healthy control group 1.84% (IQR= 1.00, 3.13) 
as compared with the hepatic steatosis group 16.58% (IQR= 9.10, 30.70). The distribution of 
liver fat within the hepatic steatosis group is shown in Figure 1. Measurements of liver fat were 
reflected in the liver biochemistry with significantly greater liver transaminases (AST and ALT) 
and serum GGT in the hepatic steatosis group. Patients with hepatic steatosis had significantly 
higher FLI [56.21 (IQR= 31.43, 72.75) vs. 18.77 (IQR= 8.00, 37.60)] and LAP [72.75 (IQR= 
47.53, 99.24) vs. 39.96 (IQR= 25.11, 53.64)] than participants in the control group.  
 
Receiver operating characteristic (ROC) curves (Figure 2) 
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Receiver Operating Characteristic (ROC) curves were constructed and AUROC with NAFLD 
defined as liver fat >5.5% on MRS. Both LAP and FLI were able to discriminate between 
patients with and without hepatic steatosis. The AUROC for LAP was 0.78 (IQR= 0.72, 0.83) 
and for FLI was 0.79 (IQR= 0.74, 0.84). There was no evidence that AUROC for LAP and FLI 
differed (P=0.49). We also considered the AUROC for BMI, waist circumference, ALT, 
triglycerides and GGT, which were 0.64 (IQR= 0.58, 0.70), 0.73 (IQR= 0.67, 0.79), 0.83 (IQR= 
0.79, 0.88), 0.74 (IQR= 0.69, 0.79) and 0.73 (IQR= 0.67, 0.78), respectively. We conducted 
exploratory pairwise comparisons between all seven of these variables and found evidence that 
both FLI and LAP were superior to waist circumferences and BMI. FLI was also superior to 
GGT (P=0.03) but not to triglycerides (P=0.10). The reverse was true for LAP, which was 
superior to triglycerides (P=0.01) but not GGT (P=0.12). Interestingly, ALT had a similar 
AUROC to both FLI and LAP. 
 
Sensitivity, specificity, positive likelihood ratios and negative likelihood ratio of FLI and LAP 
Table 2A gives the sensitivity, specificity, positive likelihood ratios and negative likelihood 
ratios for a range of 10-unit intervals for FLI. The intervals chosen were those used by Bedogni 
et al7. A cut-off of FLI ≥ 10 gives a sensitivity of 95 % and a LR- of 0.15 i.e. an individual 
without hepatic steatosis is around seven times more likely to have an FLI < 10. A cut-off of FLI 
≥ 60 gives a specificity of 91% and a LR+ of 5.10 i.e. an individual with hepatic steatosis is 
around five times more likely to have an FLI ≥ 60.  
 
Table 2B gives the sensitivity, specificity, positive likelihood ratios and negative likelihood 
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ratios for a range of 10-unit intervals for LAP. A cut-off of LAP ≥ 20 gives a sensitivity of 99% 
and LR- of 0.08 i.e. an individual without hepatic steatosis is around ten times more likely to 
have a LAP < 20. A cut-off of LAP ≥ 80 has a specificity of 94% and LR+ of 4.93 i.e. an 
individual with hepatic steatosis is around five times more likely to have an LAP ≥ 80.   
 
We report these cut-offs in particular because they yield a LR+ >5 and a LR- < 0.2 and therefore 
might be used as reasonable ‘rule-in’ and ‘rule-out’ criteria respectively.  
 
Calibration of FLI 
FLI provides a ‘predicted probability’ of a patient having hepatic steatosis. The calibration plot 
in Figure 3 addresses how satisfactory these predicted probabilities were in our cohort. We have 
established that FLI discriminates between patients with and without hepatic steatosis (using 
AUROC analysis) and this is evidenced by the horizontal separation of the two clouds of points, 
clustered at low FLI values for those without steatosis, and at higher FLI values for those with 
hepatic steatosis.  
 
We further determined how closely an individual’s actual FLI corresponds to their probability of 
having hepatic steatosis and this relates to calibration. We assessed calibration of FLI by 
grouping patients according to FLI and calculating the proportion of individuals in each group 
with hepatic steatosis. The proportion of individuals with hepatic steatosis within each decile is 
plotted in Figure 3 (solid circles) with corresponding confidence intervals. 
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If these proportions closely match the (dashed) line of equality then FLI is well calibrated and 
FLI can reliably be used as a predictive probability of hepatic steatosis. The confidence intervals 
generally include the line of equality and therefore our results indicate that the predicted 
probabilities of hepatic steatosis given by FLI are consistent with the observed percentages in our 
cohort i.e. that FLI is reasonably well calibrated. The point estimates being above the line of 
equality indicate that FLI may underestimate the probability of a patient having hepatic steatosis 
and perhaps might be considered a pragmatic lower limit. 
 
Predicting hepatocellular lipid content using FLI and LAP  
Both FLI and log-transformed LAP were linearly related to log-transformed liver fat (Figure 4). 
However, the values of log-transformed liver fat varied considerably about the regression line. 
This variability is the primary contributor to the width of the 95% PIs and hence determines the 
estimated predictive ability of each algorithm. If we consider the width of the PIs at FLI=30, a 
patient’s liver fat for this score could plausibly be between around 0% and 40%. For LAP=30, 
the predicted liver fat could plausibly be between around 0% and 45%. Varying the predictive 
values of FLI and LAP at other values remained uninformative, suggesting FLI and LAP cannot 
be used to quantitatively determine liver fat content.  
 
Discussion 
Here, we provide external validation for the use of two previously reported indices, the FLI and 
the LAP, to determine any given individual’s probability of having hepatic steatosis, based on 
simple clinical parameters. The validation in the current study was performed on a large cohort 
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of individuals with varying degrees of obesity, with and without hepatic steatosis, using 1H MRS 
measurement of liver fat, considered by many to be the gold standard, non-invasive measurement 
technique.   
 
The predictive models were originally developed using ultrasonography, a semi-quantitative 
methods capable of defining the degree of steatosis (mild, moderate or severe)28. 1H MRS 
derived measures of liver fat can accurately quantify liver fat, validated against liver biopsy 
specimens4 with normal liver fat being <5.5%4. The predictive values of FLI in this study 
compare favourably with those from Bedogni et al. 7 to ‘rule out’ or ‘rule in’ hepatic steatosis: an 
FLI cut point of 10 has a 95% vs. 98% sensitivity and a negative likelihood ratio 0.15 vs. 0.10 
respectively, whereas a FLI cut point of 60 has a specificity 91% vs. 86% and a positive 
likelihood ratio of 5.1 vs. 4.3 respectively. Thus in our study an individual without hepatic 
steatosis was around seven times more likely to have an FLI<10 and an individual with hepatic 
steatosis was around five times more likely to have an FLI>60. A cut-off of LAP ≥ 20 had a 
sensitivity of 99% and LR- of 0.08 i.e. an individual without hepatic steatosis was around ten 
times more likely to have a LAP < 20 while a cut-off of LAP ≥ 80 has a specificity of 94% and 
LR+ of 4.93 i.e. an individual with hepatic steatosis is around five times more likely to have a 
LAP ≥80.  
 
The FLI and LAP values are most useful to determine the probability of an individual having 
hepatic steatosis, but the strength of their relationship with liver fat content is insufficient for 
accurate prediction. A previous, elegant study by Kotronen et al. in a large cohort of Finnish 
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adults, using 1H MRS measurements of liver fat, developed a NAFLD liver fat score and an 
equation distinct from FLI, which has been applied to predict NAFLD and liver fat content29. 
However, in contrast to the indices discussed here, that score required measurement of fasting 
serum insulin concentrations.  
 
To date, FLI has only been validated in a small group of females (n=25) using 1H MRS measures 
of liver fat demonstrating a non-linear relationship between FLI and liver fat content, limiting its 
predictive ability21. Determining the severity of steatosis has arguably only limited clinical 
utility, mere identification of an individual as having hepatic steatosis, as part of the NAFLD 
spectrum, being sufficient to trigger prompt assessment and treatment of associated cardio-
metabolic complications, and determination of presence of non-alcoholic steatohepatitis or 
fibrosis either non-invasively or by liver biopsy, to reduce the long term risk of cardiovascular 
and hepatic complications. 
 
FLI, adopted as a surrogate marker of hepatic steatosis, has been applied in numerous 
prospective, epidemiological studies, and can predict the risk of incident type 2 diabetes 
mellitus30, the incidence of atherosclerosis and cardiovascular disease 18 and of hepatic-related 
mortality  after 15 years16. Thus, FLI values have both diagnostic and prognostic significance.  
 
Strengths of this study include the large number of well characterised individuals with liver fat 
measured by the gold standard, non-invasive method. Furthermore, the study comprised a cross-
section of individuals with normal liver fat and with hepatic steatosis (of a mild, moderate or 
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severe degree). We acknowledge a limitation of the study was that individuals were recruited 
from three different research sites, thus there was a lack of standardization of the analytical 
techniques (i.e. biochemical assays and magnetic resonance spectroscopy) between the three 
centres. However, analysis of the individual data sets from each of the three centres 
demonstrated similar results. A further limitation, inherent to these algorithms, is that although 
these values can predict the probability of hepatic steatosis, they have no predictive ability in 
identifying individuals who may have progressed along the NAFLD spectrum, with non-
alcoholic steatohepatitis, NASH or fibrosis.  
 
In summary, we provide an external validation for the use of fatty liver index, FLI and lipid 
accumulation product, LAP using magnetic resonance spectroscopy. These results provide 
reassurance about its legitimacy as a surrogate marker for hepatic steatosis.  
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Figure legends 
Figure 1. Distribution of liver fat in those with hepatic steatosis. 
Figure 2. Receiver operating characteristics (ROC) analysis of fatty liver index (FLI) to predict 
presence or absence of non-alcoholic fatty liver disease (NAFLD).  
Figure 3. The hollow circles represent individual FLI values for each patient: those circles 
(patients) at the top of the plot have hepatic steatosis and those at the bottom do not (the points 
have been artificially separated slightly so that overlapping circles are not obscured).  
Solid circles represent the percentage of patients with hepatic steatosis within each decile of FLI 
(with corresponding confidence intervals). 
Figure 4. Linear regression with 95% prediction intervals (PI) to determine whether liver fat 
content (presented as the natural logarithm of liver fat, y axis) can be predicted using FLI (x axis, 
upper graph) or LAP (x axis, lower graph).  
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Table 1. Baseline clinical, anthropometric and biochemical characteristics of participants. 
 Controls Hepatic steatosis P 
n 168 (50%) 168 (50%) - 
Male 
Female 
61 (34%) 
107 (67%) 
116 (66%) 
52 (33%) 
<0.0005 
Liver fat (%) 1.8 (1.0, 3.1) 16.6 (9.1, 30.7)) 0.0001 
Age (years) 48.6 (11.9) 50.3 (10.9) 0.19 
Weight (kg) 83.3 (72.5, 93.2) 93.4 (84.6, 104.6) 0.29 
BMI (kg.m-2) 29.2 (26.7, 32.3) 31.2 (28.9, 33.9) 0.0001 
Waist (cm) 98.4 (89.9, 104.8) 105.8 (100.5, 113.0) 0.0001 
Fasting glucose (mmol/l) 4.80 (4.50, 5.10) 5.00 (4.70, 5.40) 0.0001 
Cholesterol (mmol/l) 5.00 (4.55, 5.80) 5.50 (4.87, 6.02) 0.0135 
Triglycerides (mmol/l) 1.01 (0.80, 1.30) 1.60 (1.11, 2.32) 0.0001 
HDL (mmol/l) 1.40 (1.20, 1.68) 1.20 (1.05, 1.42) 0.0001 
LDL (mmol/l) 3.12 (2.64, 3.80) 3.30 (2.80, 3.92) 0.14 
Chol:HDL ratio 3.67 (3.00, 4.24) 4.29 (3.81, 5.26) 0.0001 
AST (u/L) 21 (18, 24) 28 (23, 35) 0.0001 
ALT (u/L) 19 (16, 26 37 (26, 56) 0.0001 
GGT (u/L) 20 (13, 29) 37 (21, 58) 0.0001 
FLI 18.8 (8.0, 37.6) 56.2 (31.3, 72.8) 0.0001 
LAP 40.0 (25.1, 53.6) 72.8 (47.5, 99.2) 0.0001 
Categorical variables compared using Chi-squared test. Continuous variables compared using the 
unpaired t-tests or Mann-Whitney U tests depending on whether data met the relevant 
distributional assumptions. Categorical variables reported as frequency (percentage) and 
continuous variables as Mean (SD) or Median (IQR). 
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Table 2. FLI and LAP cut-point table. 
FLI 
Cutpoint % SN SP LR+ LR- 
≥10 0.83 0.95 0.29 1.35 0.15 
≥20 0.67 0.86 0.53 1.82 0.27 
≥30 0.54 0.75 0.69 2.43 0.36 
≥40 0.45 0.66 0.77 2.84 0.45 
≥50 0.38 0.56 0.81 3.03 0.54 
≥60 0.26 0.44 0.91 5.10 0.61 
≥70 0.18 0.29 0.94 4.87 0.75 
≥80 0.11 0.19 0.96 4.71 0.85 
≥90 0.04 0.06 0.99 9.74 0.94 
(% = proportion of patients with an FLI ≥ cut point). 
LAP 
Cutpoint % SN SP LR+ LR- 
≥20 0.91 0.99 0.16 1.18 0.08 
≥30 0.79 0.93 0.34 1.40 0.22 
≥40 0.68 0.86 0.50 1.71 0.29 
≥50 0.50 0.70 0.69 2.29 0.43 
≥60 0.39 0.59 0.81 3.17 0.50 
≥70 0.34 0.54 0.86 3.74 0.54 
≥80 0.26 0.43 0.91 4.93 0.62 
≥90 0.19 0.33 0.94 5.20 0.72 
≥100 0.14 0.24 0.96 5.43 0.80 
≥110 0.12 0.2 0.96 5.33 0.83 
≥120 0.10 0.18 0.97 5.60 0.85 
(% = proportion of patients with a LAP ≥ cut point).  
 
